Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
Pharmaceutics, 2020 Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated
Hannes Lengauer +7 more
doaj +1 more source
Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B
Case Reports in Hepatology, 2023 Fanconi syndrome is a rare disease of generalized proximal tubule dysfunction which can be acquired secondary to certain medications, including tenofovir, a commonly used hepatitis B treatment.
Shirley X. Jiang +2 more
doaj +1 more source
Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
Life, 2021 Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB.
Tomoya Sano +6 more
doaj +1 more source
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study [PDF]
PeerJ, 2021 Background Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic ...
Pei-Yuan Su +4 more
doaj +2 more sources
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate [PDF]
Open Forum Infectious Diseases, 2019 Abstract Background In human immunodeficiency virus (HIV) treatment, tenofovir alafenamide (TAF) is associated with greater increases in all fasting cholesterol subgroups compared with tenofovir disoproxil fumarate (TDF).
Huhn, Gregory D +7 more
openaire +2 more sources
2SPD-005 Economical analysis of tenofovir alafenamide versus tenofovir-disoproxil fumarate [PDF]
Section 2: Selection, Procurement and Distribution, 2019 Background Due to the recent commercialisation of the presentations of Tenofovir Alafenamide (TAF) for HIV, there is a need to analyse the costs involved in its introduction into the public health system and its potential impact. Purpose The objective of the study is to assess the cost of using TAF instead of tenofovir-disoproxil fumarate (TDF) in a
M Camean-Castillo +9 more
openaire +1 more source
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide [PDF]
AIDS, 2018 The aim of the study was to compare the intraindividual plasma and intracellular peripheral blood mononuclear cell (PBMC) pharmacokinetics of tenofovir (TFV) and its intracellular metabolite, TFV-diphosphate (TFV-DP) in patients switched from a fixed-dose combination (FDC) tablet of TFV disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir (EVG ...
Anthony T, Podany +8 more
openaire +2 more sources
P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate [PDF]
Sexually Transmitted Infections, 2015 Background Off-target renal and bone side effects may occur with tenofovir disoproxil fumarate (TDF) use. Compared with TDF, tenofovir alafenamide (TAF) results in significantly reduced plasma tenofovir (TFV) and may have less renal and bone toxicity.
Frank Post +9 more
openaire +1 more source
BMC Infectious Diseases, 2018 Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee +7 more
doaj +1 more source
Central Asian Journal of Medical Sciences, 2020 Objectives: To provide compare of the efficacy and safety tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative and HBeAg-positive chronic hepatitis B.
Tuvshinbayar Narangerel +4 more
doaj +1 more source